Clinical Trials Browser

Phase 1/2 × Has results × poly ICLC × Clear all

NCT02078648 2025-02-03

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Phase 1/2 Completed

74 enrolled 19 charts

Glioblastoma

NCT02834052 2024-06-07

Pembrolizumab + Poly-ICLC in MRP Colon Cancer

Phase 1/2 Completed

42 enrolled 13 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colonic Neoplasms

NCT02166905 2023-02-24

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Phase 1/2 Completed

40 enrolled 15 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

NCT02332889 2018-05-04

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

Phase 1/2 Terminated

1 enrolled 6 charts

Glioma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Phase 1/2 Completed

34 enrolled 10 charts

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis